H.R. 1613 · 118th Congress · Health

Drug Price Transparency in Medicaid Act of 2023

Died in committee1.3k words Introduced Mar 17, 2023 · Latest action Mar 24, 2023

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedMar 17, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.

Congressional Research Service · summary of “Introduced in House” version · Mar 17, 2023

Who lobbies on it

26 organizations · 124 filings · Q1 2023–Q4 2024

These 26 organizations’ PACs gave $537K to 31 of the 38 members sponsoring or cosponsoring H.R. 1613 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. National Association of Chain Drug Stores 8 of 8 quarters
    “Lower healthcare costs and bring transparency to pharmacy benefit managers (PBMs) through meaningful PBM reforms. H.R. 1613 Drug Price Transparency in Medicaid Act H.R. 1770 Equitable Community Access to Pharmacist Services Act H.R. 2534 Protect 340B Act of 2023 H.R. 2816 The PBM Sunshine and Accountability Act…”

    $3.9M lobbying spend in 2024, all issuesQ4 2024 filing

  2. Teva Pharmaceuticals Usa, Inc. 8 of 8 quarters
    “…and Drug Price Transparency in Medicaid Act of 2023 (H.R. 1613), and Lower Costs, More Transparency Act (H.R. 5378); Patent reform, including the Preserve Access to Affordable Generics and Biosimilars Act (S. 142), Affordable Prescriptions for Patients Act (S. 150); Block, Report, and Suspend Suspicious Shipments Act…”

    $2.3M lobbying spend in 2024, all issuesQ4 2024 filing

  3. Kroger Co 8 of 8 quarters
    “H.R. 1613, S. 1038 - Drug Price Transparency in Medicaid Act, including issues related to PBM Spread Pricing; S. 260, H.R. 704 - Promoting Access to Diabetic Shoes Act; H.R. 1770 - Equitable Community Access to Pharmacist Services Act; S. 127 - Pharmacy Benefit Manager Transparency Act; Issues related to Food as…”

    $1.6M lobbying spend in 2024, all issuesQ4 2024 filing

23 more organizations, every filingPROUpgrade

Organizations that named H.R. 1613 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

3 actions · newest first
  1. Mar 24, 2023Referred to the Subcommittee on Health.
  2. Mar 17, 2023Referred to the House Committee on Energy and Commerce.
  3. Mar 17, 2023Introduced in House